Heart failure with preserved ejection fraction: how can we approach it?
Keywords:
Heart failure, Ejection fraction, Biomarkers, Phenotype, Treatment
Abstract
Heart failure with preserved ejection fraction (ICFEp) is a syndrome with a prevalence of 1 - 5.5% that is associated with old age and various inflammatory and metabolic mechanisms that trigger structural alterations that result in characteristic signs and symptoms. Diagnosis is made with clinical characteristics and echocardiographic study, and despite its implication in the mortality of the affected individuals, there are no effective measures to reduce adverse effects, so the management is oriented to each comorbidity, and It has even been proposed to take the therapy towards subgroups with defined characteristics. For this review, a bibliographic search on different databases was carried out, prioritizing information obtained from randomized studies and meta-analysis.
Downloads
Download data is not yet available.
Disciplines:
Internal Medicine, CardiologyReferences
1. Redfield M. Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2016;375(19):1868-1877.
2. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016;18(8):891-975.
3. Oktay A, Shah S. Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews. 2014;11(1):42-52.
4. Oktay A, Rich J, Shah S. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2013;10(4):401-410.
5. Gómez E. Identificación de pacientes con falla cardiaca y función sistólica preservada: Un estudio epidemiológico regional (I-PREFER Study) – Colombia. Revista Colombiana de Cardiología. 2013;20(2):58-67.
6. Tibrewala A, Yancy C. Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics. 2019;15(1):9-18.
7. Tromp J, MacDonald M, Tay W, Teng T, Hung C, Narasimhan C et al. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018;138(24):2763-2773.
8. Gupta D, Shah A, Castagno D, Takeuchi M, Loehr L, Fox E et al. Heart Failure With Preserved Ejection Fraction in African Americans. JACC: Heart Failure. 2013;1(2):156-163.
9. Lai Y, Wang L, Gladwin M. Insights into the Pulmonary Vascular complications of heart failure with Preserved Ejection Fraction. The Journal of Physiology. 2018;.
10. Borlaug B. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507-515.
11. Cikes M, Claggett B, Shah A, Desai A, Lewis E, Shah S et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(8):689-697.
12. Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;69(5):556-569.
13. Zile M, Litwin S. Heart Failure with a Preserved Ejection Fraction. En: Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Editors. Braunwald heart disease a textbooks of cardiovascular medicine. Eleventh edition. Philadelphia: ELSEVIER; 2019. P. 1287-1344
14. Lam C, Voors A, de Boer R, Solomon S, van Veldhuisen D. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792.
15. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24(4):252-258.
16. Iwano H, Little W. Heart failure: What does ejection fraction have to do with it?. Journal of Cardiology. 2013;62(1):1-3.
17. Mentz R, Kelly J, von Lueder T, Voors A, Lam C, Cowie M et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281-2293.
18. Hegde S, Claggett B, Shah A, Lewis E, Anand I, Shah S et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017;136(11):982-992.
19. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure. 2015;8(1):33-40.
20. Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation. 2016;134(1):73-90.
21. Pandey A, Patel K, Vaduganathan M, Sarma S, Haykowsky M, Berry J et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(12):975-982.
22. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16).
23. de Denus S, O’Meara E, Desai A, Claggett B, Lewis E, Leclair G et al. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. New England Journal of Medicine. 2017;376(17):1690-1692.
24. Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017;104(5):407-415.
25. Martin N, Manoharan K, Thomas J, Davies C, Lumbers R. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2018;.
26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli F. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews. 2014;20(2):193-201.
27. Solomon Scott, Mc Murray John, E et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction- PARAGON HF The NEJM 2019 ; September 1: Pag1-11.
28. Sueta Daisuki, Yamamoto Eiichiro, et al. H2FPEF Score as a Prognostic Value in HFpEF patients. American Journal of Hypertension, 2019: Pag 1-37
2. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016;18(8):891-975.
3. Oktay A, Shah S. Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews. 2014;11(1):42-52.
4. Oktay A, Rich J, Shah S. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2013;10(4):401-410.
5. Gómez E. Identificación de pacientes con falla cardiaca y función sistólica preservada: Un estudio epidemiológico regional (I-PREFER Study) – Colombia. Revista Colombiana de Cardiología. 2013;20(2):58-67.
6. Tibrewala A, Yancy C. Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics. 2019;15(1):9-18.
7. Tromp J, MacDonald M, Tay W, Teng T, Hung C, Narasimhan C et al. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018;138(24):2763-2773.
8. Gupta D, Shah A, Castagno D, Takeuchi M, Loehr L, Fox E et al. Heart Failure With Preserved Ejection Fraction in African Americans. JACC: Heart Failure. 2013;1(2):156-163.
9. Lai Y, Wang L, Gladwin M. Insights into the Pulmonary Vascular complications of heart failure with Preserved Ejection Fraction. The Journal of Physiology. 2018;.
10. Borlaug B. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507-515.
11. Cikes M, Claggett B, Shah A, Desai A, Lewis E, Shah S et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(8):689-697.
12. Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;69(5):556-569.
13. Zile M, Litwin S. Heart Failure with a Preserved Ejection Fraction. En: Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Editors. Braunwald heart disease a textbooks of cardiovascular medicine. Eleventh edition. Philadelphia: ELSEVIER; 2019. P. 1287-1344
14. Lam C, Voors A, de Boer R, Solomon S, van Veldhuisen D. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792.
15. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24(4):252-258.
16. Iwano H, Little W. Heart failure: What does ejection fraction have to do with it?. Journal of Cardiology. 2013;62(1):1-3.
17. Mentz R, Kelly J, von Lueder T, Voors A, Lam C, Cowie M et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281-2293.
18. Hegde S, Claggett B, Shah A, Lewis E, Anand I, Shah S et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017;136(11):982-992.
19. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure. 2015;8(1):33-40.
20. Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation. 2016;134(1):73-90.
21. Pandey A, Patel K, Vaduganathan M, Sarma S, Haykowsky M, Berry J et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(12):975-982.
22. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16).
23. de Denus S, O’Meara E, Desai A, Claggett B, Lewis E, Leclair G et al. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. New England Journal of Medicine. 2017;376(17):1690-1692.
24. Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017;104(5):407-415.
25. Martin N, Manoharan K, Thomas J, Davies C, Lumbers R. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2018;.
26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli F. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews. 2014;20(2):193-201.
27. Solomon Scott, Mc Murray John, E et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction- PARAGON HF The NEJM 2019 ; September 1: Pag1-11.
28. Sueta Daisuki, Yamamoto Eiichiro, et al. H2FPEF Score as a Prognostic Value in HFpEF patients. American Journal of Hypertension, 2019: Pag 1-37
How to Cite
(1)
Orozco-Burbano, J. D.; Cabrera-Velasco, C. E.; Ortiz-Andrade, J. I.; López-Garzón, N. A. Heart Failure With Preserved Ejection Fraction: How Can We Approach It?. Rev. Fac. Cienc. Salud Univ. Cauca 2020, 22, 26-33.
Published
2020-07-01
Section
Artículos de revisión
.png)
